GABA-A receptor subtypes in the brain: a paradigm for CNS drug discovery?
The clinical importance of benzodiazepines, barbiturates and general anesthetics, all of which act through the γ-aminobutyric acid (GABA)-A neurotransmitter receptor, is testament to its significance as a CNS drug target. These drugs were all developed before there was any understanding of the diver...
Gespeichert in:
Veröffentlicht in: | Drug Discovery Today 2003-05, Vol.8 (10), p.445-450 |
---|---|
1. Verfasser: | |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | The clinical importance of benzodiazepines, barbiturates and general anesthetics, all of which act through the γ-aminobutyric acid (GABA)-A neurotransmitter receptor, is testament to its significance as a CNS drug target. These drugs were all developed before there was any understanding of the diversity of this receptor gene family. Recent studies using genetically modified mice and GABA-A receptor-subtype-selective compounds have helped to delineate the function of some of these subtypes, and have revealed that it might be possible to develop a new generation of selective drugs with improved profiles or novel applications.
Target validation continues to be a critical challenge in drug discovery, particularly for central nervous system disorders. This review describes how the use of sophisticated genetic mouse models in combination with behavioural pharmacology can be a powerful approach to defining drug targets. |
---|---|
ISSN: | 1359-6446 1878-5832 |
DOI: | 10.1016/S1359-6446(03)02703-X |